Protocol For Collecting Data On Patients With Childhood Cancer



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:12/19/2018
Start Date:June 8, 2000
End Date:May 2025
Contact:Melissa M Hudson, MD
Email:referralinfo@stjude.org
Phone:866-278-5833

Use our guide to learn which trials are right for you!

Progress in the development of curative therapy for pediatric malignancies has resulted in
increasing numbers of long-term childhood cancer survivors. This protocol is a means to
provide continuing review of outcome and late toxicity for all patients actively being
treated and previously treated for childhood cancer at St. Jude Children's Research Hospital.

Previously at St. Jude Children's Research Hospital, monitoring and reporting of late
treatment sequelae developing in protocol participants have occurred at the discretion of
individual investigators. A formal mechanism for coordinating long-term follow-up data
collection of late cancer-related toxicity did not exist within the institution, nor did a
central data repository to facilitate correlation of clinical and treatment factors
predisposing to toxicity. Central coordination of late effects monitoring and reporting at
St. Jude offers the potential benefit of facilitating timely communication about
life-threatening or unanticipated late toxicity to investigators developing contemporary
therapeutic studies and monitoring predisposed survivors who may benefit from preventive or
corrective interventions.

This study centralizes the late effects monitoring and reporting of St. Jude therapeutic
studies which have been completed under the auspices of one umbrella protocol. This protocol
is not an independent research study, but rather a means to aggregate outcome and late
effects reporting regarding all patients actively being treated and previously treated at St.
Jude Children's Research Hospital for the diagnosis of childhood cancer. Data collected on
the patient will include only those data obtained through clinical staff or Cancer Registry
encounters that are documented in the medical record or provided by the patient or family on
follow-up forms. All monitored patients will have information provided regarding status
(alive/expired), relapse, subsequent malignancies, and death for any cause. Clinical
outcomes, toxicity and late effects monitoring planned in the study on which the patient was
originally enrolled will be collected by the principal investigators of that study. Subjects
will then be followed in the After Completion of Therapy on an annual basis for 10 years from
diagnosis (or 10 years from completion of salvage therapy for relapse) or until they are at
least 18 years of age. They will undergo specific screening laboratory, diagnostic imaging
studies, and subspecialty consultations as medically indicated by predisposing cancer
treatment exposures. At the time of discharge from ACT clinic the subject will begin annual
lifetime follow-up by the St. Jude Cancer Registry.

Inclusion Criteria:

- All St Jude patients actively being followed or treated for childhood cancer

Exclusion Criteria:

- St. Jude consult only patients

- St. Jude patients permanently discharged from care and follow-up Permanently
discharged patients include patients who have electively transferred their oncologic
care to another institution, those who are noncompliant with recommended follow-up or
those leaving the institution against medical advice.

- Patients referred to St. Jude for limited care on phase 1 protocol.
We found this trial at
1
site
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Melissa M Hudson, MD
Phone: 866-278-5833
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials